<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444235</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N-CSM-III/01/08</org_study_id>
    <nct_id>NCT01444235</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery</brief_title>
  <official_title>A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N Versus Custodiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. F. Köhler Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. F. Köhler Chemie GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the cardioprotective effects and safety of two cardioplegic solutions
      (solutions used during a cardiac arrest in the heart surgery) in patients undergoing
      cardiopulmonary bypass for coronary artery bypass surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this investigation is to compare the cardioprotective effects and safety of
      two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients
      undergoing cardiopulmonary bypass for coronary artery bypass surgery. The study design is a
      prospective, double blind, multicenter, randomized, Phase III comparison study intended to
      demonstrate non-inferiority in surgical outcome between Custodiol and Custodiol-N as
      determined by CK-MB area under the curve (primary endpoint), catecholamine
      requirement(cumulative dose) and cardiac Troponin T, occurrence of comorbid events
      postoperatively (e.g., myocardial infarction).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CK-MB area under the curve within 24 hours</measure>
    <time_frame>Up to 24 hours after the aortic clamp release</time_frame>
    <description>Measurements will be carried out at the following timepoints: 4,8,12,16,20,24 hours (± 30 min) after release of the aortic cross clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamine requirement</measure>
    <time_frame>24 hours (cumulative dose)</time_frame>
    <description>Catecholamine requirement on surgical ICU within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK-MB peak</measure>
    <time_frame>Up to day 5</time_frame>
    <description>CK-MB peak on the days 2, 3, 4 and 5 after removal of aortic cross clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality any time during post-op through Day 30</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Mortality will be documented at any time during post-op through Day 30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol-N</intervention_name>
    <description>Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes</description>
    <arm_group_label>Custodiol-N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol</intervention_name>
    <description>Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused</description>
    <arm_group_label>Custodiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The study population will be selected from patients of either sex with coronary artery
        disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery.

          1. Patients &gt;/=35 and &lt;/=80 years of age

          2. Male or female with 2 or 3 vessel coronary disease, who are scheduled for elective CBP
             surgery for coronary revascularisation

          3. Presence of definite CAD for which surgical intervention is deemed necessary, without
             evidence of ongoing infarction.

             Patients with unstable angina can be included as long as there is no objective
             (negative cardiac isoenzymes in the immediate six hours preceding CABG, current
             intravenous use of nitrate therapy) or subjective (absence of prolonged symptoms
             suggestive of coronary insufficiency that do not respond to pharmacologic
             intervention) evidence of myocardial necrosis.

          4. Eligibility for Swan-Ganz-Catheter

          5. Able to understand character and individual consequences of the clinical trial and to
             provide written informed consent to participate in the study

          6. No evidence of severe organic or psychiatric disease by history or physical
             examination

          7. No history of alcohol abuse, illicit drug use, significant mental illness, physical
             dependence to any opioid, or no any history of drug abuse or addiction within 12
             months of study enrollment.

        Exclusion Criteria:

          1. Patients undergoing valve repair or replacement

          2. History of recent (&lt; 6 weeks) Q-wave myocardial infarction

          3. Left ventricular ejection fraction &lt; 35% (as assessed by any one of the following:
             contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)

          4. Patients on intra-aortic balloon devices or with history of previous coronary artery
             bypass surgery

          5. Pregnant or lactating patients

          6. Patients who have participated in any other investigational studies within 30 days
             previous to enrollment

          7. Patients in cardiogenic shock (defined as a systolic BP &lt; 90 mmHg for over one hour
             despite inotropic and chronotropic support)

          8. Patients with severe chronic obstructive lung disease (FEV1 &lt; 50%)

          9. Previous cardiac valvular disease (clinical relevant)

         10. Dialysis or creatinine &gt; 2 mmol/L

         11. BMS-Stent &lt; 4 weeks

         12. DES-Stent &lt; 6 month

         13. Guidance depended Plavix therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor Szabo, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiac Surgery of University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaus Pizanis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian Wagner, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Herz- und Gefäßchirurgie, Universitäts-Krankenhaus Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thorsten Doenst, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Misfeld, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig GmbH, Klinik für Herzchirurgie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Herzchirugie, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD, ACVB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

